Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Catabasis Pharma (CATB)

Catabasis Pharma (CATB)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
8.54 -0.64 (-6.97%) 09/08/21 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 8.54 unch (unch) -
Quote Overview for Wed, Sep 8th, 2021
Day Low
8.46
Day High
9.21
Open 9.21
Previous Close 9.18 9.18
Volume 98,800 98,800
Avg Vol 395,311 395,311
Stochastic %K 70.21% 70.21%
Weighted Alpha -50.43 -50.43
5-Day Change -1.43 (-14.34%) -1.43 (-14.34%)
52-Week Range 6.31 - 47.82 6.31 - 47.82
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,337
  • Shares Outstanding, K 3,904
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,300 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -12.84
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/09/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.81
  • Number of Estimates 3
  • High Estimate -0.64
  • Low Estimate -1.14
  • Prior Year -3.36
  • Growth Rate Est. (year over year) +75.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.31 +35.34%
on 08/20/21
Period Open: 9.30
10.26 -16.76%
on 09/02/21
-0.76 (-8.17%)
since 08/06/21
3-Month
6.31 +35.34%
on 08/20/21
Period Open: 12.96
15.72 -45.67%
on 06/16/21
-4.42 (-34.10%)
since 06/08/21
52-Week
6.31 +35.34%
on 08/20/21
Period Open: 39.12
47.82 -82.14%
on 01/29/21
-30.58 (-78.17%)
since 09/08/20

Most Recent Stories

More News
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc....

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming...

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information...

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information...

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

CATB : 8.54 (-6.97%)
Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies

Xontogeny LLC , a Boston-based accelerator that provides seed-stage investments along with strategic and operational support to early-stage life science companies, unveiled five of its latest portfolio...

LABP : 22.93 (+0.58%)
CATB : 8.54 (-6.97%)

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

3rd Resistance Point 9.76
2nd Resistance Point 9.49
1st Resistance Point 9.01
Last Price 8.54
1st Support Level 8.26
2nd Support Level 7.99
3rd Support Level 7.51

See More

52-Week High 47.82
Fibonacci 61.8% 31.96
Fibonacci 50% 27.07
Fibonacci 38.2% 22.17
Last Price 8.54
52-Week Low 6.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro